FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% objective response rate and 80% disease control rate in renal cell carcinoma (RCC) cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT / 1:30 p ...